NEW YORK (Reuters Health)—After an immune-related adverse event, the risk-reward ratio for an anti-PD-1 (anti-programmed death-1) or anti-PD-L1 (anti-programmed death ligand-1) rechallenge seems to be acceptable if patients are closely monitored, researchers say. “The immune checkpoint inhibitors anti-PD-1 and anti-PD-L1 have proven efficacy in the treatment of many cancers, but patients may experience immune-related adverse…
Risk Assessment & Treatment in APS Patients
The pathogenesis of antiphospholipid syndrome (APS) is complicated and may involve local inflammation, vasculopathy, pregnancy complications and thrombosis. During the 2019 ACR State-of-the-Art Clinical Symposium, Lisa Sammaritano, MD, addressed the risk assessment and treatment of APS patients…
Vaccines & Rheumatology Patients
Vaccines are often safe for rheumatology patients, but precautions may be needed, said Brian Schwartz, MD, at the 2019 ACR State-of-the-Art Clinical Symposium…
Insight into Clinical Trials for Lupus
Research into lupus treatments suffered a setback after the failure of anifrolumab in clinical trials. However, during the 2019 ACR State-of-the-Art Clinical Symposium, Richard Furie, MD, outlined the possibilities of multiple new lupus therapies under investigation…
New Research Examines the Use of Natural Dietary Supplements by RA Patients
The popularity of natural dietary supplements has grown worldwide, with many adults using them to manage musculoskeletal conditions. But for RA patients, little is known about the risk of side effects and potential adverse drug interactions when taking these supplements with standard RA therapies. New research examined the supplement use patterns of RA patients…
Myositis Autoantibodies as Biomarkers
A recent study details the autoantibodies of patients with myositis, confirming most patients carry these antibodies. The results also describe how myositis-specific autoantibodies can be used to identify distinct clinical subsets of idiopathic inflammatory myopathy…
Contemporary Prevalence of Gout & Hyperuricemia in the U.S.
Using 2007–2016 data from NHANES, a nationally representative survey of American men and women, Chen-Xu et al. set out to estimate the current prevalence rates and decadal trends of gout and hyperuricemia in the U.S.
Upadacitinib Monotherapy Effective in Refractory Rheumatoid Arthritis
NEW YORK (Reuters Health)—Monotherapy with the JAK1-selective inhibitor upadacitinib is effective in patients with active rheumatoid arthritis who have an inadequate response to methotrexate, according to results from the SELECT-MONOTHERAPY phase 3 trial. As many as two-thirds of patients with rheumatoid arthritis receiving methotrexate monotherapy fail to achieve satisfactory disease control. Oral therapy with upadacitinib…
Peripheral Manifestations of Spondyloarthritis
A recent study evaluated the factors associated with the presence of peripheral manifestations of spondyloarthritis (SpA), which affects more than half of patients with SpA. Researchers found that being older, HLAB27 negative and having a history of psoriasis were associated with these symptoms…
U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug
WASHINGTON (Reuters)—On May 20, the U.S. Supreme Court threw out a lower court ruling that had revived hundreds of lawsuits accusing Merck & Co. of failing to properly warn patients of debilitating thigh-bone fractures as a result of taking its osteoporosis drug alendronic acid (Fosamax). The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit…
- « Previous Page
- 1
- …
- 124
- 125
- 126
- 127
- 128
- …
- 345
- Next Page »